

Eric Bruckert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4563317/publications.pdf>

Version: 2024-02-01

22
papers

4,669
citations

516710

16
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

6466
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	3.0	22
2	High <sc>TG</sc> to <sc>HDL</sc> ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3367.	4.0	44
3	The position of functional foods and supplements with a serum LDL-C lowering effect in the spectrum ranging from universal to care-related CVD risk management. <i>Atherosclerosis</i> , 2020, 311, 116-123.	0.8	28
4	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
5	Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1068-1076.	2.6	10
6	Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review. <i>Journal of Clinical Lipidology</i> , 2019, 13, 31-39.	1.5	25
7	An increased waist-to-hip ratio is a key determinant of atherosclerotic burden in overweight subjects. <i>Acta Diabetologica</i> , 2018, 55, 741-749.	2.5	30
8	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. <i>Scientific Reports</i> , 2018, 8, 1943.	3.3	25
9	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	2.2	262
10	Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. <i>Atherosclerosis</i> , 2018, 277, 66-71.	0.8	12
11	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
12	A nutraceutical approach (Armolidip Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. <i>Atherosclerosis Supplements</i> , 2017, 24, 1-15.	1.2	83
13	Is lomitapide a life-saving drug in homozygous familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1841-1842.	1.8	3
14	A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The Tj ETQq0 0 0 rg-BB/Overlook 10 Tf 5	0.5	1
15	HbA1c increase is associated with higher coronary and peripheral atherosclerotic burden in non diabetic patients. <i>Atherosclerosis</i> , 2016, 255, 102-108.	0.8	54
16	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	1.5	98
17	Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey. <i>Atherosclerosis Supplements</i> , 2014, 15, 46-51.	1.2	21
18	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	1.7	316

#	ARTICLE	IF	CITATIONS
19	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology, 2014, 2, 655-666.	11.4	473
20	Comparison of Efficacy and Safety Assessment of Fluvastatin in Patients < 65 Years Versus ≥65 Years of Age. American Journal of Cardiology, 2005, 96, 1142-1148.	1.6	9
21	Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets. Country Review Ukraine, 2005, 7, L16-L20.	0.8	1
22	Prevention of cardiovascular events in elderly hypercholesterolemic patients. Current Atherosclerosis Reports, 1999, 1, 9-15.	4.8	3